

Semisynthetic Analogues of Toxiferine I and Their Pharmacological Properties at $\alpha 7$ nAChRs, Muscle-type nAChRs, and the Allosteric Binding Site of Muscarinic M₂ Receptors

Darius P. Zlotos,^{*,†} Christian Tränkle,[‡] Ulrike Holzgrabe,[§] Daniela Gündisch,[⊥] and Anders A.

Jensen^{||}

[†]The German University in Cairo, Department of Pharmaceutical Chemistry, New Cairo City, 11835 Cairo, Egypt

[‡]Pharmacology and Toxicology Section, Institute of Pharmacy, Rheinische Friedrich-Wilhelms-University, D-53121 Bonn, Germany

[§]Institute of Pharmacy and Food Chemistry, University of Würzburg, 97074 Würzburg, Germany

[⊥]Department of Pharmaceutical Sciences, Daniel K. Inouye College of Pharmacy, University of Hawai'i at Hilo, Hilo, HI 96720, United States

^{||}Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark

* Corresponding author E-mail: darius.zlotos@guc.edu.eg. Tel: +20 2 2758 1041. Fax: +20 2 2758 1041.

Figure S1. NOESY spectrum of **3** (aliphatic section, 600 MHz, CDCl₃)

Figure S2. ¹H NMR (CDCl₃, 600 MHz) and ¹³C NMR (100 MHz) spectra of **2**

Figure S3. ¹H NMR (CDCl₃, 600 MHz) and ¹³C NMR (100 MHz) spectra of **3**

Figure S4. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **3a**

Figure S5. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **3b**

Figure S6. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **3c**

Figure S7. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **2a**

Figure S8. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **2b**

Figure S9. ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR (100 MHz) spectra of **2c**




Figure S1. NOESY spectrum of compound **3** (aliphatic section, 600 MHz, CDCl₃)




Figure S2. ^1H NMR (CDCl₃, 600 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) spectra of compound 2




Figure S3. ^1H NMR (CDCl_3 , 600 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **3**




Figure S4. ^1H NMR (DMSO- d_6 , 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **3a**




Figure S5. ^1H NMR (DMSO- d_6 , 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **3b**




Figure S6. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **3c**




Figure S7. ^1H NMR ($\text{DMSO-}d_6$, 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **2a**




Figure S8. ^1H NMR (DMSO- d_6 , 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **2b**




Figure S9. ^1H NMR ($\text{DMSO-}d_6$, 400 MHz) and ^{13}C NMR (100 MHz, including DEPT-135 subspectrum) of compound **2c**